A promising combination for multiple myeloma received FDA approval as a second-line therapy. The approval of teclistamab (Tecvayli) plus daratumumab hyaluronidase (Darzalex Faspro) stipulates use in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results